title: Efficacy of screening donors for antibodies to the hepatitis C virus to prevent transfusion-associated hepatitis: final report of a prospective trial.
abstract: Routine screening of blood donors for anti-hepatitis C virus (HCV) has been implemented in most developed countries. However, the independent efficacy of such screening has not been established in a controlled, prospective study. We tracked 478 patients transfused with anti-HCV-negative blood by first-generation enzyme-linked immunoassay (EIA) between July 1989 and May 1990 and compared the incidence of transfusion-associated hepatitis and HCV infections with that found among 280 patients transfused with blood unscreened for anti-HCV during the immediately preceding year. Of the 280 patients who had received transfusions before donors were screened for anti-HCV, 27 (9.6%) developed posttransfusion hepatitis and 1 additional patient seroconverted to anti-HCV without evidence of hepatitis, for a risk of posttransfusion HCV infection of 10.7% (28 of 262 recipients seronegative for anti-HCV before transfusion). Of the 478 patients transfused after July 1989 with blood screened for anti-HCV, only 9 (1.9%) developed posttransfusion hepatitis for a risk reduction of 80%. Seven of the 9 residual cases of hepatitis were caused by HCV (7 of 456 recipients seronegative before transfusion or 1.5%) for a risk reduction of transfusion-associated HCV infection of 86%. In retrospect, an anti-HCV positive donor was detected by second-generation immunoassay in 4 (57%) of the 7 HCV cases from the study cohort and in 19 of the 23 (83%) cases from whom all donor samples were available for testing in the historical cohort. No additional infectious donors were detected by third-generation immunoassay or serum HCV-RNA by polymerase chain reaction.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Internal Medicine, Hospital General Universitari Vall d'Hebron, Barcelona, Spain.
authors.forename: A
authors.initials: A
authors.lastname: González
authors.forename: J I
authors.initials: JI
authors.lastname: Esteban
authors.forename: P
authors.initials: P
authors.lastname: Madoz
authors.forename: L
authors.initials: L
authors.lastname: Viladomiu
authors.forename: J
authors.initials: J
authors.lastname: Genesca
authors.forename: E
authors.initials: E
authors.lastname: Muñiz
authors.forename: J
authors.initials: J
authors.lastname: Enríquez
authors.forename: X
authors.initials: X
authors.lastname: Torras
authors.forename: J M
authors.initials: JM
authors.lastname: Hernández
authors.forename: J
authors.initials: J
authors.lastname: Quer
mesh_terms: D000328:Adult; D000368:Aged; D000914:Antibodies, Viral / Q000097:blood*; D001782:Blood Donors; D001803:Blood Transfusion; D016022:Case-Control Studies; D005260:Female; D016174:Hepacivirus / Q000235:genetics / Q000276:immunology*; D006526:Hepatitis C / Q000517:prevention & control / Q000635:transmission* / Q000821:virology; D006801:Humans; D007118:Immunoassay / Q000706:statistics & numerical data; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012367:RNA, Viral / Q000097:blood; D012189:Retrospective Studies; D012307:Risk Factors
chemical_list: D000914:Antibodies, Viral; D012367:RNA, Viral